HeartBeam Partners with LIVMOR for Cloud Based Remote Monitoring Portal
February 02 2022 - 5:21PM
Business Wire
LIVMOR to Develop HeartBeam Branded Version of
the FDA Registered LIVMOR Halo+ Portal
HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage
digital healthcare company with a proprietary ECG telemedicine
technology for heart attack detection, today announced it has
signed a partnership agreement with LIVMOR Inc., a digital health
solutions company, to build a HeartBeam branded version of LIVMOR’s
Halo+ FDA cleared turnkey solution for remote patient monitoring
(“RPM”) to connect physicians and patients.
Under the terms of the agreement LIVMOR will develop a HeartBeam
branded version, the HeartBeam Platform, of the LIVMOR RPM platform
customized for HeartBeam products, with senior executives of both
companies supervising the project.
“Utilizing LIVMOR’s FDA cleared RPM platform will allow us to
meet our schedule for FDA submission of our first product, an
easy-to-use heart attack detection software solution for Emergency
Department settings,” said Branislav Vajdic, PhD, Chief Executive
Officer and Founder of HeartBeam. “LIVMOR has successfully
developed a patient-engaging remote monitoring system of critical
physiological biomarkers which we believe can be adapted to utilize
with our Emergency Department software solution for more accurate
MI detection. LIVMOR’s experience in the regulatory process is an
important benefit, providing support and assistance for us as we
seek to submit the HeartBeam Platform for FDA clearance. We look
forward to working with the team at LIVMOR to ready our software
for submission to the FDA later this year.”
About LIVMOR
Founded in 2016, LIVMOR is a digital health solutions company
whose mission is to assist physicians and medical professionals in
addressing the global chronic disease epidemic by providing a
patient-engaging remote monitoring system of critical physiological
biomarkers. LIVMOR’s goals are to dramatically improve patient
outcomes and to significantly reduce healthcare system costs with
better quality data for diagnosis and treatment of chronic
diseases. For more information, visit www.livmor.com.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital
healthcare company with proprietary ECG telemedicine technology
that will redefine the way high risk cardiovascular patients are
diagnosed in an ambulatory setting at any time and any place. Its
breakthrough solution employs a reusable, credit card sized, 3D
vector ECG recording device and cloud-based software capable of
assisting a physician in diagnosing a wide range of cardiovascular
disease. HeartBeam is initially focusing on a huge unmet need of
helping diagnose heart attacks in patients outside of a medical
institution. No single lead ECG technology can offer this value to
patients and their physicians. This underserved market is several
times larger than the cardiac arrhythmia detection market based on
the prevalence of patients with coronary artery disease at high
risk of heart attack. For more information visit
www.heartbeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are “forward-looking statements.” While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our recently filed Registration Statement on Form S-1, which can
be found on the SEC’s website at www.sec.gov. We urge you to
consider those risks and uncertainties in evaluating our
forward-looking statements. We caution readers not to place undue
reliance upon any such forward-looking statements, which speak only
as of the date made. Except as otherwise required by the federal
securities laws, we disclaim any obligation or undertaking to
publicly release any updates or revisions to any forward-looking
statement contained herein (or elsewhere) to reflect any change in
our expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220202005972/en/
Media and Investor Relations Contact: Chris Tyson
Executive Vice President MZ North America Direct: 949-491-8235
BEAT@mzgroup.us www.mzgroup.us
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From May 2024 to Jun 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2023 to Jun 2024